Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Sibutramine

A serotonin and noradrenaline reuptake inhibitor that reduces appetite. Developed in Nottingham, England, in 1988 and approved in the United States in 1997 to treat obesity alongside a diet, it was withdrawn from most markets in 2010. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?It began life as a potential antidepressant: during development the research was redirected towards appetite control, and the molecule became a weight-loss medicine.

SibutramineGo to the active ingredient →
SibutramineActive ingredientSibutramineCat. No. P-S040-001CAS 106650-56-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.